Cora Capital Advisors LLC Purchases 217 Shares of Johnson & Johnson $JNJ

Cora Capital Advisors LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,216 shares of the company’s stock after buying an additional 217 shares during the quarter. Cora Capital Advisors LLC’s holdings in Johnson & Johnson were worth $491,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in JNJ. Highline Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at $48,000. von Borstel & Associates Inc. bought a new position in Johnson & Johnson in the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the 1st quarter worth about $52,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.6%

NYSE JNJ opened at $177.71 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock’s fifty day moving average price is $174.09 and its 200-day moving average price is $161.97. The stock has a market cap of $427.99 billion, a P/E ratio of 19.01, a P/E/G ratio of 2.25 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. UBS Group increased their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.40.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.